SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (date of earliest event reported): July 7, 2009
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
|
|
|
1301
Harbor Bay Parkway
Alameda,
California 94502
(Address
of principal executive offices)
(510)
521-3390
(Registrant's
telephone number, including area code)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements made in this Report that
are not historical facts may constitute forward-looking statements that are
subject to risks and uncertainties that could cause actual results to differ
materially from those discussed. Such risks and uncertainties include
but are not limited to those discussed in this report and in BioTime's other
reports filed with the Securities and Exchange Commission. Words such as
“expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,”
“seeks,” “estimates,” and similar expressions identify forward-looking
statements.
Section
1 - Registrant’s Business and Operations
Item 1.01- Entry into a Material
Definitive Agreement.
On July
7, 2009, our subsidiary, Embryome Sciences, Inc., entered into an agreement
under which Millipore Corporation will become a worldwide distributor of
ACTCellerate™ human progenitor cell lines. Millipore’s initial
offering of Embryome Sciences’ products will include six novel progenitor cell
lines and optimized ESpanTM
growth media for the in
vitro propagation of each progenitor cell line. The companies
anticipate jointly launching 35 cell lines and associated ESpan™ growth media
within the coming 12 months.
Derived
from human embryonic stem cells but not fully differentiated into specific cell
types, each ACTCellerate™ line provides a convenient, highly purified source of
progenitor cells that may have applications in drug discovery, research, and the
development of therapeutic products.
Millipore
will be Embryome Sciences’ exclusive third party distributor of the products
covered by the agreement, although Embryome Sciences retains the right to sell
the products to its own customers. Embryome Sciences will provide the
products to Millipore on consignment and will be paid on a quarterly basis for
products sold. Embryome Sciences will receive additional annual
payments from Millipore, based on a percentage of annual sales, if annual sales
exceed certain milestone amounts.
The
agreement will have a term of five years, subject to annual renewal if the
parties so elect, and subject to Millipore’s right to terminate the agreement at
any time upon 60 days notice. Either party may also terminate the
agreement in the case of an uncured breach or default by the other
party.
Section
9-Financial Statements and Exhibits
Item
9.01- Financial Statements and Exhibits.
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release Dated July 9, 2009
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
BIOTIME,
INC.
|
|
|
|
|
|
|
|
Date: July
9, 2009
|
By
/s/ Steven A.
Seinberg
|
|
|
Chief
Financial Officer
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Press
Release Dated July 9, 2009
|
|
|
|
|
|
|
|
|